Latest Early Cancer Detection News

Page 2 of 3
BCAL Diagnostics has secured national ethics approval to establish a large-scale registry tracking the clinical impact of its BREASTESTplus blood test for breast cancer diagnosis, aiming to enhance doctor adoption and reimbursement prospects.
Ada Torres
Ada Torres
3 Dec 2025
BCAL Diagnostics is preparing to launch its Avantect® pancreatic and ovarian cancer blood tests in Australia by January 2026, following key regulatory approvals and promising clinical data. The company also broadens the reach of its BREASTESTplus™ breast cancer test, targeting a larger segment of women with dense breast tissue.
Ada Torres
Ada Torres
19 Nov 2025
BCAL Diagnostics has secured key partnerships and a $10 million convertible note facility to expand its cancer detection tests across Australia and New Zealand, marking steady commercial progress in Q3 2025.
Ada Torres
Ada Torres
31 Oct 2025
INOVIQ Limited has raised $11.5 million through a $9.5 million placement and a $2 million share purchase plan to accelerate the development and commercialisation of its EXO-OC ovarian cancer test and exosome therapeutic program.
Ada Torres
Ada Torres
13 Oct 2025
Imagion Biosystems has completed manufacturing its MagSense® HER2 imaging agent, progressing toward a Phase 2 clinical trial with strong collaborations and a recent AU$3.5 million capital raise.
Ada Torres
Ada Torres
7 Oct 2025
Imagion Biosystems has completed the second tranche of its $3.5 million placement, raising $2.85 million to advance its proprietary MagSense® imaging technology targeting breast, prostate, and ovarian cancers.
Ada Torres
Ada Torres
29 Sept 2025
INOVIQ Limited has obtained exclusive worldwide rights to novel ovarian cancer biomarker IP from UniQuest, propelling its EXO-OC™ test closer to commercial launch. The test’s exceptional sensitivity and specificity position it as a potential breakthrough in early cancer detection.
Ada Torres
Ada Torres
26 Sept 2025
BCAL Diagnostics has partnered with US-based ClearNote Health to exclusively distribute innovative blood tests for early detection of pancreatic and ovarian cancers in Australia and New Zealand, starting early 2026.
Ada Torres
Ada Torres
18 Sept 2025
Rhythm Biosciences has formalised a strategic co-marketing partnership with the Know Your Lemons Foundation to promote its geneType Breast Cancer Risk Assessment Test, expanding access to early detection tools for women in the US and Australia.
Ada Torres
Ada Torres
28 Aug 2025
Rhythm Biosciences has announced a $3.75 million placement to accelerate the commercial launch of its ColoSTAT® cancer detection test and expand its geneType™ product suite into key markets. The capital raise includes director participation and attaching options, pending shareholder approval.
Ada Torres
Ada Torres
18 Aug 2025
Imagion Biosystems has completed the first tranche of its $3.5 million capital raising, issuing 45 million new shares to strengthen its financial position ahead of a key shareholder vote.
Ada Torres
Ada Torres
11 Aug 2025
Rhythm Biosciences has responded to an ASX price query following a sudden surge in its share price and trading volume, confirming no undisclosed information is driving the activity.
Ada Torres
Ada Torres
6 Aug 2025